PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. The live webcast of the conference call may be accessed by using the following link: Nanox Q4 Earnings Webcast. The link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.
Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for more accurate diagnostics and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD, a subsidiary of Nanox Imaging, is an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision.
Contacts
Media Contact
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Mike Cavanaugh
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.06 |
Daily Change: | -0.12 -2.32 |
Daily Volume: | 998,763 |
Market Cap: | US$322.930M |
July 01, 2025 June 05, 2025 May 22, 2025 April 17, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load